

# Gallego Study

...for GA Secondary to AMD



## Dry Macular Degeneration

*A Phase II, Multicenter, Randomized, Single-Masked, Sham-Controlled Study to Assess Safety, Tolerability, and Efficacy of FHTR2163 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration (GALLEGO)*

**Principal Investigator:**  
Dr. Matthew Ohr

*Pre-baseline FAF image obtained via a Heidelberg platform 84-336 days prior to the screening visit is required.*

### **INCLUSION CRITERIA:**

- At least 60 years of age with bilateral clinical diagnosis of GA of the macular secondary to AMD
- ETDRS score of 24 letters or better (approximate Snellen equivalent of at least 20/320)
- Baseline FAF image shows GA lesion size of at least 2.54mm<sup>2</sup> and not more than 25.4 mm<sup>2</sup>

### **EXCLUSION CRITERIA:**

- GA secondary to a condition other than AMD in either eye
- Absence of any hyperfluorescences pattern adjacent to GA area in the study eye
- Presence of diffuse-trickling, patchy, or minimal (focal) hyperfluorescence pattern adjacent to GA area in the study eye

**Ohio State Department of Ophthalmology & Visual Science • 614-293-5287 • [Research@osumc.edu](mailto:Research@osumc.edu)**

This research is not being conducted by the Columbus Chalmers P. Wiley Ambulatory Care Center. The research has not been reviewed by the Institutional Review Board of the Chalmers P. Wiley VA. The VA is not responsible for any costs incurred by participating in the research study.